Market Overview - The A-share pharmaceutical and biotechnology index fell by 0.68%, underperforming the CSI 300 index by 0.11 percentage points and the ChiNext index by 1.97 percentage points, ranking 19th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index rose by 2.38%, outperforming the Hang Seng China Enterprises Index by 0.48 percentage points [4] R&D Progress - Last week, Qinhai Pharmaceutical's GH55 and Innovent Biologics' IBI343 clinical applications were newly undertaken [5] - Sangfor's 608 is currently in Phase III clinical trials; Aosaikang's ASK092 is in Phase II; and Hansoh Pharmaceutical's HS-20093 is in Phase I clinical trials [5] Industry Insights - The pharmaceutical and biotechnology sector is driven by innovation (including overseas expansion, AI, and new technologies), performance validation, policy benefits, and seasonal market movements, with a focus on innovative drugs and CXO in the short term [6] - AI in healthcare and pharmaceuticals, brain-computer interfaces, and small nucleic acid drugs are identified as high-potential sub-themes [6] - Continuous attention is required on the outcomes of collaborations post-JPM conference, clinical data of innovative drugs, and performance realization [6] Investment Strategy for 2026 - The investment focus in the pharmaceutical sector should increasingly emphasize the clinical value logic, addressing clinical needs of patients and doctors, influenced by domestic medical insurance policies and global expansion [7] - The clinical value is expected to command higher premiums, leading to a favorable outlook on the innovative drug supply chain and innovative medical devices [7]

Core Viewpoint - The Chinese innovative drug sector is experiencing rapid growth, positioning itself as a global leader in drug development, with significant investments and collaborations from major pharmaceutical companies [2][8][30]. Group 1: Market Dynamics - The price of experimental monkeys has surged from 3,000 yuan to 100,000 yuan, indicating a high demand in the innovative drug sector [1]. - By 2025, China is projected to rank second globally in new drug clinical trials, with its pipeline accounting for 30% of the global total [2]. - In 2024, Chinese innovative drug companies completed 94 overseas licensing transactions, representing 44% of the national total, with over 100 transactions exceeding $100 billion in the first ten months of 2025 [6][30]. Group 2: Challenges in Traditional Pharmaceutical Sector - The generic drug sector is facing significant challenges, with a projected 5.5% decline in revenue for 2024 and over 30% of companies experiencing losses [5]. - Major pharmaceutical companies are increasingly collaborating with Chinese innovative drug firms to mitigate the risks associated with patent expirations, which could lead to a revenue gap exceeding $300 billion in the next five years [10][30]. Group 3: Advantages of Chinese Innovative Drugs - China offers a cost-effective and efficient environment for drug development, with clinical trial costs significantly lower than in the U.S. [20][21]. - The average time for clinical trial approvals in China has been reduced from 60 to 30 working days, and the average new drug application approval time has decreased to approximately 130 days [14]. - Chinese pharmaceutical companies are increasingly moving from "me-too" and "me-better" drugs to original innovations, with a notable increase in the number of innovative drug projects [27]. Group 4: Global Positioning and Future Outlook - Despite the rapid growth of Chinese innovative drugs, the overall market value of Chinese biotech companies remains significantly lower than their U.S. counterparts, capturing only 5% to 10% of global new drug revenues [30][31]. - Chinese companies are establishing commercial centers in global pharmaceutical hubs to enhance their commercialization capabilities, marking a shift towards becoming major players in the global market [37][38]. - The transition from biotech firms to large multinational pharmaceutical companies is seen as a critical step in the global battle for market share and innovation [38].

Market Overview - The Hong Kong stock market experienced a decline on January 19, with the Hang Seng Index falling by 0.76% [1] - The pharmaceutical sector faced significant losses, particularly in the innovative drug industry, with major stocks like Alibaba Health and others in the AI medical concept continuing to drop [1][10] Innovative Drug Sector Performance - The innovative drug sector saw a broad adjustment, with leading companies experiencing declines: China Biologic Products fell by 6.19%, CanSino Biologics by 3%, and others like Innovent Biologics and Hansoh Pharmaceutical dropped over 4% [1][13] - The Hong Kong Stock Connect Innovative Drug ETF (520880) fell by 2.72%, marking a three-day losing streak and losing both the 10-day and 60-day moving averages, with trading volume increasing by over 50% to 390 million HKD [11][12] Factors Influencing Market Sentiment - The adjustments in the innovative drug sector are attributed to the market digesting sentiments post the JPMorgan Healthcare Conference, which concluded on January 15, and a cautious outlook ahead of upcoming earnings forecasts for 2025 [4][15] - The market is currently in a phase of waiting for actual revenue and profit data, leading to a tendency to avoid uncertainty, particularly for companies that are not yet profitable or are in the early stages of commercialization [4][15] Future Outlook for Innovative Drug Sector - The innovative drug sector is expected to see significant earnings forecasts from leading companies in 2025, which could present opportunities for valuation recovery if results exceed expectations [5][16] - The sector's long-term fundamentals remain strong, with projections indicating that the total overseas licensing revenue for innovative drugs could reach 135.7 billion USD in 2025, reflecting global recognition of Chinese pharmaceutical R&D capabilities [16] - Continued policy support is anticipated, with the National Medical Products Administration expected to approve 76 innovative drugs in 2025, the highest globally, and ongoing optimization of the review and approval processes [16] Investment Strategy - The Hong Kong Stock Connect Innovative Drug ETF (520880) is positioned as a high-elasticity T+0 investment tool, focusing exclusively on innovative drug R&D companies [5][16] - The ETF's index features a significant concentration of leading companies, with the top ten holdings accounting for over 73% of the total weight, indicating a strong representation of the sector's core strengths [6][17]

Core Insights - The conference titled "New Ecosystem of Three Medical Linkages" was held to discuss clinical innovation and technology empowerment in healthcare, supported by Jiangsu Haosen Pharmaceutical and organized by the China Medical Education Association [1] - The third-generation EGFR-TKI drug, Amivantamab, has been officially included in the new national medical insurance directory for postoperative adjuvant therapy of EGFR mutation-positive non-small cell lung cancer (NSCLC), marking a significant advancement in accessibility for patients [1] Group 1 - The conference emphasized the importance of "Three Medical Linkages" as a core approach to deepen healthcare reform and promote the Healthy China initiative, with experts advocating for collaborative efforts to maximize policy benefits and innovation outcomes [2] - Experts discussed the strategic layout of the national policy encouraging pharmaceutical innovation, optimizing drug review and approval processes, and improving medical insurance payment mechanisms, providing clear policy expectations for the development and application of innovative drugs [2] - The conference highlighted the challenges of lung cancer, which has the highest incidence and mortality rates among malignant tumors in China, with approximately 85% of cases being NSCLC and about 30% of patients diagnosed at an operable early stage facing postoperative recurrence risks [2] Group 2 - The rapid development of Chinese-origin third-generation EGFR-TKI drugs, represented by Amivantamab, offers new options for postoperative adjuvant therapy in early-stage NSCLC, with evidence from the ART study supporting its efficacy for patients in stages II to IIIB [3] - The inclusion of Amivantamab in the national medical insurance directory significantly enhances its affordability, reducing treatment disparities among patients from different regions and economic backgrounds, and facilitating the distribution of quality targeted therapy resources to grassroots medical institutions [3]

Core Insights - The Hong Kong Wealth Management Summit and the 12th Hong Kong Stock Top 100 Awards recognized Hansoh Pharmaceutical as an "Annual Medical Innovation Pioneer" and included it in the "Top 100 Comprehensive Strength" list, highlighting its status as a core benchmark for innovation in the Hong Kong pharmaceutical sector [1] Group 1: Company Performance - In the first half of 2025, Hansoh Pharmaceutical achieved revenue of 7.434 billion yuan, representing a year-on-year growth of 14.3%, with innovative drugs and collaborative product sales accounting for 82.7% of total revenue, serving as the main driver of growth [2] - The company has established four R&D centers in Shanghai, Lianyungang, Changzhou, and Maryland, USA, employing over 1,900 specialized R&D personnel, thus creating a complete innovation system from compound screening to clinical research [2] Group 2: Global Expansion - Hansoh Pharmaceutical successfully obtained two marketing approvals for Amelot® in the UK, marking it as the first Chinese original third-generation EGFR-TKI to enter the mainstream European market, laying a solid foundation for future expansion into the EU [3] - The company announced a collaboration with Indian pharmaceutical company Glenmark for exclusive rights to Amelot® across multiple regions, with a total potential value exceeding 1 billion USD, further demonstrating its achievements in internationalization [3] - Hansoh has established a global innovation network through bilateral business development collaborations, having introduced 12 cooperative projects, with 10 entering clinical stages and 2 achieving commercialization, forming a dual innovation model of "independent R&D + external collaboration" [3] Group 3: Industry Context - The domestic innovative drug industry is entering a critical phase of "commercialization and global breakthrough," with policy support, explosive overseas transactions, and the emergence of profitability points creating vast opportunities for industry development [3] - Recognition as an "Annual Medical Innovation Pioneer" reflects the capital market's acknowledgment of Hansoh's past achievements and expectations for its future growth potential [3]

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Viewpoints - The US tumor gene testing industry is accelerating, and there are positive domestic opportunities. The market for gene testing has low penetration rates but high growth potential, particularly in colorectal cancer early screening, treatment selection, and minimal residual disease (MRD) testing, which are all billion-dollar markets [3][8] - The report emphasizes the importance of innovation in the pharmaceutical sector, highlighting that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, particularly in innovative drugs. Companies like Heng Rui Medicine and Han Sen Pharmaceutical have made significant strides in innovation [5][41] - The report suggests that the aging population and the increasing demand for healthcare services will continue to drive growth in the pharmaceutical industry, supported by a multi-layered payment system and advancements in technology such as AI and brain-computer interfaces [41][42] Summary by Sections Market Performance - From January 12 to January 16, the pharmaceutical index fell by 0.68%, with 202 stocks rising and 261 falling. The top gainers included Baolait (up 48.76%) and Hualan Biological (up 32.72%), while the biggest losers were Sunflower (down 37.48%) and *ST Changyao (down 33.33%) [5][25][27] Gene Testing Industry - The report highlights the rapid development of the US tumor gene testing industry, with companies like Natera and Guardant Health showing impressive revenue growth. Natera's Q4 2025 revenue reached $660 million, a 39% year-on-year increase, while Guardant Health's revenue for the same period was $280 million, also up 39% [8][9] - The report notes that the domestic gene testing market is expected to grow rapidly, with companies like BGI and Edan Diagnostics actively positioning themselves in the MRD and early screening sectors [24][22] Investment Recommendations - The report recommends focusing on strong fundamentals and undervalued stocks in the innovative drug sector, including companies like Xinyi Tai, Zecjin Pharmaceutical, and Shanghai Yizhong. It also suggests monitoring emerging technologies in healthcare, such as AI and brain-computer interfaces, which are expected to see significant advancements in 2026 [5][45][44] - Specific investment combinations for January include Xinyi Tai, China Biologic Products, and Sanofi Pharmaceutical, among others [45]

Market Overview - The Hong Kong stock market experienced a broad adjustment on January 19, with the Hang Seng Index falling nearly 1% and the pharmaceutical sector declining alongside the market [1] - The Hong Kong Stock Connect Medical ETF, Huabao (159137), saw a drop of 2%, frequently trading at a premium, while major stocks like WuXi Biologics fell over 5% [1][2] - AI healthcare leaders JD Health and Alibaba Health both dropped more than 1% [1] Pharmaceutical Sector Performance - The medical sector opened lower and continued to decline, with the Hong Kong Stock Connect Innovation Drug ETF (520880) dropping over 2% during the session [1] - Key stocks in the innovation drug sector, such as BeiGene and CanSino Biologics, also fell by more than 2%, while several others, including China Biologic Products and 3SBio, dropped over 4% [1] Trading Activity - The Hong Kong Stock Connect Innovation Drug ETF (520880) was noted for its persistent premium trading, indicating strong buying interest, with a transaction volume exceeding 200 million yuan [3] - The ETF's price was reported at 0.541, down 1.99%, with a trading volume of 4.65 billion [4] Future Outlook - The National Medical Products Administration of China announced that by 2025, 76 innovative drugs are expected to be approved, placing China at the forefront globally [4] - The total transaction volume for overseas licensing of Chinese innovative drugs is projected to exceed 130 billion USD in the same year [4] - Analysts believe that the Chinese innovative drug sector is entering a phase of simultaneous benefits from "going global, technology, and policy," leading to a revaluation of innovative drug stocks [5] Investment Opportunities - Starting in January 2026, several innovative drug companies will release their earnings forecasts for 2025, presenting potential valuation recovery opportunities for those exceeding expectations [6] - The Hong Kong Stock Connect Innovation Drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovation Drug Select Index, which has distinct advantages, including a focus on pure innovative drug companies and a significant weighting of leading firms [6][7] - The top ten innovative drug leaders account for over 73% of the index, highlighting the strength of the sector [7]

Group 1 - The Hong Kong Innovation Drug ETF (159570) has experienced a 2.5% decline for three consecutive days, with a trading volume exceeding 800 million yuan, and has attracted over 1 billion yuan in the last five days [1][3] - As of January 16, the latest scale of the Hong Kong Innovation Drug ETF (159570) has surpassed 26.2 billion yuan, leading its peers in the same category [1] - The majority of the weighted stocks in the ETF's index have shown negative performance, with notable declines including Kelun-Bio down over 5%, Innovent Biologics and Hansoh Pharmaceutical down over 4%, and others down over 3% [3][4] Group 2 - The 44th JPMorgan Healthcare Conference took place from January 12 to 15, featuring several Chinese innovative pharmaceutical companies, including WuXi AppTec and BeiGene, among others [5] - Huatai Securities noted that the JPM conference and the upcoming annual report cycle in February could serve as catalysts for the market, which is currently at a relative bottom, with expectations for new highs in the innovative drug sector [5] - Zhongtai Securities highlighted multiple catalysts in the pharmaceutical sector, including significant data disclosures from multinational corporations and various business development deals, indicating a positive outlook for the innovative drug industry [5][6] Group 3 - The 2026 JPMorgan Conference is expected to showcase Chinese innovative drugs as a global highlight, with over 20 Chinese pharmaceutical companies participating [7] - Companies like HengRui are projected to see a 25%+ growth in innovative drug revenue by 2026, with several key drugs and indications expected to be approved in the next two years [7] - Notable developments include RC148's licensing deal worth up to 5.6 billion USD between Rongchang Bio and AbbVie, and various clinical trial advancements from companies like Summit Therapeutics and Eifang Bio [8]

港股创新药概念股走低，翰森制药跌超4%，信达生物、中国生物制药、三生制药、科伦博泰生物-B跌超3%。 受盘面影响，多只港股创新药相关ETF跌超2%。 | 代码 名称 现价 | 类型 | | 涨跌 涨跌幅 ▲ | | --- | --- | --- | --- | | 520850 跨 N港股通医疗ETF易方达 | | 0.978 | -0.025 -2.49% | | 159570 跨 港股通创新药ETF T+0 | | 1.690 | -0.038 -2.20% | | 520700 跨 港股创新药ETF基金 T+0 | | 1.652 | -0.035 -2.07% | | 513780 跨 港股创新药50ETF T+0 | | 1.713 | -0.036 -2.06% | | 520970 跨 港股通创新药ETF嘉实 T+0 0.924 | | | -0.019 -2.01% | 有券商表示，创新药核心资产仍将上行，小核酸、体内CAR新机遇层出不穷。创新药BD是长期产业趋势，是中国创新药力量进入世界舞 台的价值兑现，对于已授权MNC的核心资产将随着临床进展持续兑现价值。除此以外，未来仍要锚定前沿技术平 ...